Description

Meet Lumara: A New Contender in Severe Asthma

In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market. With launch roughly 12 months out, early conversations with payers and providers have begun, and the competitive set—Dupixent, Fasenra, Tezspire, Nucala—is well established. We frame the stakes, surface emerging access vulnerabilities, and set the tone for an eight-part, intelligence-driven series built for time-constrained market access and brand leaders.

What you’ll learn

• The current access landscape for specialty meds in severe asthma
• Typical launch challenges for new entrants in entrenched TAs
• Why Lumara represents a realistic, high-stakes competitor
• The competitive-intelligence themes we’ll unpack across the series

Featured segments

• Three Strategic Questions Every Entrant Must Answer
• What the Market Looks Like Today — quick stats and payer trends
• In the Shoes of a Payer — early positioning challenges for Lumara

About the series & how it was made
The Lumara Series is both an educational flyover of biologic commercialization and a live demo of what consumer-grade GenAI tools can produce—fast and affordably. Imperfections aside, the direction is transformative. Genflare acts as your CI partner, connecting dots and translating signals into action.